Colorectal carcinoma with extremely low CA19-9.
OBJECTIVE
The aim of this study is to determine the significance of postoperative sequential measurements of serum CA19-9 in patients with extremely low serum level.


METHODS
Serum level of CA19-9 of 1096 patients who underwent surgery was measured preoperatively and every three months after surgery for 5 years. Patients with CA19-9 level of less than 2 U/mL at the time of diagnosis were defined as Extremely Low CA19-9 (ELCA).


RESULTS
One hundred and seven patients (9.8%) were ELCA. Of these, 86 underwent surgery with curative intent. Serum levels of CA19-9 in patients who did not undergo curative resection (N = 12) and who developed recurrence (N = 10) were less than 2.0 U/mL in all occasions during followup. In all patients without recurrence, serum level of CA19-9 also remained less than 2.0 U/mL.


CONCLUSIONS
In patients with extremely low CA19-9, who consist of 9.8% of colorectal carcinoma cases, postoperative sequential measurement of serum level of CA19-9 contributed neither to assessment of curability of surgical resection nor to detection of recurrence.
Kawamura
Yutaka J
YJ
Department of Surgery, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan. kawamura@omiya.jichi.ac.jp
Tokumitsu
Aika
A
Sasaki
Junichi
J
Tsujinaka
Shingo
S
Maeda
Takafumi
T
Mizogami
Ken
K
Konishi
Fumio
F
J Clin Oncol. 2006 Nov 20;24(33):5313-27
17060676
BMJ. 2002 Apr 6;324(7341):813
11934773
J Clin Oncol. 2006 Jan 20;24(3):386-93
16365182
World J Surg. 2008 Jun;32(6):1130-7
18340483
Anticancer Res. 2002 Jul-Aug;22(4):2311-6
12174919
Hepatogastroenterology. 2002 Jan-Feb;49(43):160-4
11941943
Cancer. 1985 Jul 15;56(2):277-83
2408729
J Surg Oncol. 2006 Aug 1;94(2):132-7
16847905
J Surg Oncol. 1997 Dec;66(4):238-43
9425326
BMC Cancer. 2003 Oct 06;3:26
14529575
Ann Oncol. 1995 Jul;6(6):581-7
8573538
Br J Surg. 1997 May;84(5):666-9
9171758
Int J Oncol. 2002 Feb;20(2):403-11
11788909
Dis Colon Rectum. 1987 Apr;30(4):273-7
3470172
Clin Oncol (R Coll Radiol). 2004 May;16(3):196-203
15191007
J Clin Oncol. 2005 Nov 20;23(33):8512-9
16260687
Hepatogastroenterology. 1999 Mar-Apr;46(26):914-9
10370638
Ann Surg Oncol. 2007 Apr;14(4):1272-84
17211733
Hepatogastroenterology. 2003 May-Jun;50(51):696-9
12828063
Cancer Res. 1996 Jan 15;56(2):330-8
8542588
J Surg Res. 2005 Apr;124(2):169-74
15820244
Int J Biol Markers. 1995 Apr-Jun;10(2):100-6
7561233
Eur J Surg Oncol. 2002 Jun;28(4):418-23
12099653
Anticancer Res. 2000 Nov-Dec;20(6D):5195-8
11326694
Int J Clin Oncol. 2001 Feb;6(1):45-9
11706527
Anticancer Res. 1994 Nov-Dec;14(6B):2819-25
7872725
Anticancer Res. 2007 Jul-Aug;27(4C):2861-4
17695461
Cancer Res. 1998 Feb 1;58(3):512-8
9458099
Cochrane Database Syst Rev. 2002;(1):CD002200
11869629
Dis Colon Rectum. 2004 Feb;47(2):227-32
15043294
Br J Cancer. 1991 Jun;63(6):975-6
2069854
World J Gastroenterol. 2007 Oct 28;13(40):5357-9
17879406
J Am Coll Surg. 2003 Sep;197(3):386-91
12946793
Hepatogastroenterology. 1999 Mar-Apr;46(26):905-8
10370636